Table 2.
All patients (n=209) | ||
---|---|---|
Median age at diagnosis, yr (range) | 63 (45–83) | |
Sex (male, female) [n (%)] | 205, 4 (98, 2%) | |
Stage IIIB, IV [n (%)] | 61, 148 (29, 71%) | |
ECOG scale performance status [n (%)] | 0 | 42 (20) |
1 | 115 (55) | |
2 | 46 (22) | |
3 | 6 (3) | |
4 | 0 (0) | |
Histological subtype [n (%)] | Adenocarcinoma | 81 (39) |
Squamous cell carcinoma | 49 (23) | |
Non-small cell lung cancer, NOS | 65 (31) | |
Large cell carcinoma | 7 (3) | |
Others | 7 (3) | |
Highest pain level at diagnosis (before initiation of chemotherapy) [n (%)] | None (level 0) | 42 (20) |
Mild (level 1–3) | 26 (12) | |
Moderate (level 4–6) | 46 (22) | |
Severe (level 7–10) | 95 (46) | |
Pain level of the entire cohort at diagnosis (before initiation of chemotherapy) | Median, level 6 | |
Opioid requirement at diagnosis, OME day−1 (before initiation of chemotherapy) [n (%)] | None (0 mg day−1 OME) | 77 (37) |
Minimal (0.01–4.99 mg day−1 OME) | 44 (21) | |
Moderate (5–29.99 mg day−1 OME) | 48 (23) | |
High (≥30 mg day−1 OME) | 40 (19) | |
Opioid requirement of entire cohort at diagnosis (before initiation of chemotherapy) | Average, 28.7 mg day−1 OME Median, 2.6 mg day−1 OME |